Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Risedronate for SRE prevention in metastatic prostate cancer
NCT00216060Phase 3Terminated
- Start
- Oct 2003
- Primary completion
- Feb 2008
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 3 trial of risedronate in Metastatic Prostate Cancer (mPC). Started Oct 2003; status: terminated.
02
Drugs
risedronate
03
Conditions
Metastatic Prostate Cancer (mPC)
Beyond the preview
Go deeper on NCT00216060.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00216060.